Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 2/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MERTK | Q12866 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9899877 | 0.97 | SCN9A (0.39) | SCN9APARP1USP30L3MBTL1LMNA | |
| SCHEMBL9896963 | 0.91 | SCN9A (0.41) | SCN9APARP1USP30L3MBTL1LMNA | |
| SCHEMBL9896392 | 0.91 | FFAR4 (0.36) | L3MBTL1LMNAMAPTPOLBMAPK1 | |
| SCHEMBL9897924 | 0.91 | HPGDS (0.36) | L3MBTL1LMNAPOLBMAPK1 | |
| SCHEMBL16223963 | 0.91 | SCN9A (0.34) | SCN9APARP1USP30BRD4SUV39H2 | |
| SCHEMBL9898251 | 0.90 | EPHX2 (0.38) | L3MBTL1LMNAPOLBMAPK1 | |
| SCHEMBL9897842 | 0.90 | CCNT1 (0.37) | L3MBTL1LMNAPOLBMAPK1 | |
| SCHEMBL1441956 | 0.89 | MAPK1 (0.34) | L3MBTL1LMNABRD4POLBMAPK1 | |
| SCHEMBL9898441 | 0.88 | SCN9A (0.40) | SCN9APARP1USP30L3MBTL1LMNA | |
| SCHEMBL9898789 | 0.88 | EPHX2 (0.35) | L3MBTL1LMNABRD4POLBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9376442-B2 | Methylpyrrolopyrimidinecarboxamides | TAKEDA GMBH (DE) | 2016-06-28 | — | — | US | disclosed |
| US-20150073001-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | ASTRAZENECA AB (SE) | 2015-03-12 | — | — | US | disclosed |
| US-8927557-B2 | Methylpyrrolopyrimidinecarboxamides | TAKEDA GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| EP-2470536-B1 | Methylpyrrolopyrimidinecarboxamides | TAKEDA GMBH (DE) | 2014-11-12 | — | — | EP | disclosed |
| US-20120149721-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149721-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | PDE5A, PDE12, PDE4A | SCN9A 2014/4885PARP1 255/4885USP30 3041/4885 |
| US-20150073001-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | PDE12, PDE5A, PDE4A | SCN9A 2421/4885PARP1 630/4885USP30 3451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.